case_images: PMC8093620_01
case_images: PMC8093620_02
case_images: PMC8093620_03
case_images: PMC8093620_04
case_images: PMC8093620_05
case_images: CT imaging of best disease response of patients: Case 1 at beginning of therapy (A1) and 4 months after receiving carboplatin+pemetrexed chemotherapy and sintilimab (A2) Case 2 at beginning of therapy (B1) and 5 months after receiving carboplatin+pemetrexed chemotherapy and sintilimab (B2) Case 3 at beginning of therapy (C1) and 2 months after receiving carboplatin+pemetrexed chemotherapy and pembrolizumab(C2) Case 4 at beginning of therapy (D1) and 10 months after receiving carboplatin+pemetrexed chemotherapy and pembrolizumab (D2) Case 5 at beginning of therapy (E1) and 6 months after treatment with carboplatin, pemetrexed, and pembrolizumab for 4 cycles followed by pembrolizumab maintenance (E2).
case_images: fonc-11-633522-g001.jpg
case_images: PMC8093620_05_fonc-11-633522-g001.jpg
case_images: f1
case_images: Only one patient (Case 5) had squamous carcinoma, and she was also the only patient with a CR.  Figure 1  displays the representative chest CT images of all the patients' best responses.